Melphalan-Prednisolone and Vincristine-Doxorubicin-Dexamethasone Chemotherapy followed by Prednisolone/Interferon Maintenance Therapy for Multiple Myeloma: Japan Clinical Oncology Group Study, JCOG0112-Reference-Cited by-同舟云学术

Melphalan-Prednisolone and Vincristine-Doxorubicin-Dexamethasone Chemotherapy followed by Prednisolone/Interferon Maintenance Therapy for Multiple Myeloma: Japan Clinical Oncology Group Study, JCOG0112

Published:2011-01-19 Issue:4 Volume:41 Page:586-589
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:Japanese Journal of Clinical Oncology

Author:

Chou T.,Tobinai K.,Uike N.,Asakawa T.,Saito I.,Fukuda H.,Mizoroki F.,Ando K.,Iida S.,Ueda R.,Tsukasaki K.,Hotta T.,

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/41/4/586/5270280/hyq245.pdf

Reference16 articles.

1. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.

2. Phase III Study of Ranimustine, Cyclophosphamide, Vincristine, Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple Myeloma: A Japan Clinical Oncology Group Study, JCOG 9301

3. Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents

4. Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

5. INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches;Journal of Clinical Medicine;2021-04-23

2. Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials;OncoTargets and Therapy;2015-06

3. Risk of secondary primary malignancies in maintenance therapy for multiple myeloma;International Journal of Hematologic Oncology;2013-08

4. Lymphoma Study Group of JCOG;Japanese Journal of Clinical Oncology;2011-12-06